OFIX Quote, Financials, Valuation and Earnings

InfuSystem Holdings, Inc. has a net margin of -1.01% compared to Orthofix Medical, Inc.'s net margin of 5.62%. Orthofix Medical, Inc.'s return on equity of -19.94% beat InfuSystem Holdings, Inc.'s return on equity of 11.83%.

Orthofix Medical, Inc. has a consensus price target of $18.25, signalling upside risk potential of 36.5%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.90 which suggests that it could grow by 60.39%. Given that InfuSystem Holdings, Inc. has higher upside potential than Orthofix Medical, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Orthofix Medical, Inc..

Orthofix Medical, Inc. has a beta of 0.750, which suggesting that the stock is 25.028% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.665, suggesting its more volatile than the S&P 500 by 66.488%.

Orthofix Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Orthofix Medical, Inc. quarterly revenues are $219.9M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.2M. Orthofix Medical, Inc.'s net income of -$2.2M is lower than InfuSystem Holdings, Inc.'s net income of $2M. Notably, Orthofix Medical, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 29.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical, Inc. is 0.64x versus 1.36x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -1.01% compared to Orthofix Medical, Inc.'s net margin of -316.61%. Orthofix Medical, Inc.'s return on equity of -19.94% beat Plus Therapeutics, Inc.'s return on equity of --.

Orthofix Medical, Inc. has a consensus price target of $18.25, signalling upside risk potential of 36.5%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1735.78%. Given that Plus Therapeutics, Inc. has higher upside potential than Orthofix Medical, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Orthofix Medical, Inc..

Orthofix Medical, Inc. has a beta of 0.750, which suggesting that the stock is 25.028% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Orthofix Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Orthofix Medical, Inc. quarterly revenues are $219.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Orthofix Medical, Inc.'s net income of -$2.2M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Orthofix Medical, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical, Inc. is 0.64x versus 4.80x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Repligen Corp. has a net margin of -1.01% compared to Orthofix Medical, Inc.'s net margin of 6.71%. Orthofix Medical, Inc.'s return on equity of -19.94% beat Repligen Corp.'s return on equity of 2.4%.

Orthofix Medical, Inc. has a consensus price target of $18.25, signalling upside risk potential of 36.5%. On the other hand Repligen Corp. has an analysts' consensus of $186.28 which suggests that it could grow by 49.06%. Given that Repligen Corp. has higher upside potential than Orthofix Medical, Inc., analysts believe Repligen Corp. is more attractive than Orthofix Medical, Inc..

Orthofix Medical, Inc. has a beta of 0.750, which suggesting that the stock is 25.028% less volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.545%.

Orthofix Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical, Inc. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.

Orthofix Medical, Inc. quarterly revenues are $219.9M, which are larger than Repligen Corp. quarterly revenues of $197.9M. Orthofix Medical, Inc.'s net income of -$2.2M is lower than Repligen Corp.'s net income of $13.3M. Notably, Orthofix Medical, Inc.'s price-to-earnings ratio is -- while Repligen Corp.'s PE ratio is 144.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical, Inc. is 0.64x versus 9.58x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -1.01% compared to Orthofix Medical, Inc.'s net margin of -0.2%. Orthofix Medical, Inc.'s return on equity of -19.94% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.

Orthofix Medical, Inc. has a consensus price target of $18.25, signalling upside risk potential of 36.5%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $29.59 which suggests that it could grow by 17.29%. Given that Orthofix Medical, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Orthofix Medical, Inc. is more attractive than Tandem Diabetes Care, Inc..

Orthofix Medical, Inc. has a beta of 0.750, which suggesting that the stock is 25.028% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.626, suggesting its more volatile than the S&P 500 by 62.563%.

Orthofix Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Orthofix Medical, Inc. quarterly revenues are $219.9M, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Orthofix Medical, Inc.'s net income of -$2.2M is lower than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Orthofix Medical, Inc.'s price-to-earnings ratio is -- while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical, Inc. is 0.64x versus 1.67x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.